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The modulation of endocannabinoid (EC) levels and the activation of 
cannabinoid receptors are seen as promising therapeutic strategies in a 
variety of diseases, including Alzheimer’s disease (AD). We aimed to evaluate 
the effect of the pharmacological and genetic inhibiton of anandamide (AEA)-
degrading enzyme in a mouse model of AD (5xFAD). Pharmacological 
inhibition of the fatty acid amide hydrolase (FAAH) had little impact on the 
expression of key enzymes and cytokines as well as on the cognitive 
impairment and plaque deposition and gliosis in 5xFAD mice. CB1 blockade 
exacerbated inflammation in this transgenic mouse model of AD. The genetic 
inactivation of FAAH led to increases in the expression of inflammatory 
cytokines. At the same time, FAAH-null 5xFAD mice exhibited a behavioral 
improvement in spatial memory that was independent of the level of anxiety 
and was not CB1-mediated. Finally, mice lacking FAAH showed diminished 
soluble amyloid levels, neuritic plaques and gliosis. These data reinforce the 
notion of a role for the endocannabinoid system in neuroinflammation and 
open new perspectives on the relevance of modulating endocannabinoid 
levels in the inflammed brain. 
 




A: amyloid-beta peptide 
AD: Alzheimer’s disease 
AEA: arachidonylethanolamide, anandamide 
APP: amyloid precursor protein 
COX-2: cyclooxygenase-2 
ECS: endocannabinoid system 
FAAH: fatty acid amide hydrolase 
GFAP: glial fibrillary acidic protein 
Iba1: Ionized calcium-binding adapter molecule 1 
IL1b: interleukin 1-beta 
IL6: interleukin 6 
iNOS: inducible nitric oxide synthase 




PS1: presenilin 1 
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Neuroinflammation is a key feature shared by many neurodegenerative 
conditions, including Alzheimer’s disease (AD). The neuroinflammatory 
reaction in this disease is thought to be provoked mainly by the deposition of 
the amyloid-beta peptide (A) in the form of neuritic plaques in the brain 
parenchyma which, together with the formation of neurofibrillary tangles of tau 
protein, constitute the neuropathologic hallmarks of AD (Wyss-Coray, 2006; 
Querfurth and LaFerla, 2010). 
 
The role of neuroinflammation in neurodegenerative diseases is still 
controversial (see Cameron and Landreth, 2010 and Wyss-Coray and 
Rogers, 2012, for recent reviews). The predominant view indicates that 
inflammatory cytokines are released, mostly from glial cells, as a 
consequence of amyloid deposition and neuronal death, leading to a toxic 
millieu that aggravates the progression of the disease (Mrazk and Griffin, 
2005). However, recent data support the notion of potentially beneficial effects 
of some cytokines that could play neurotrophic roles and dampen the 
damaging effects of amyloid accumulation (Shaftel et al, 2008). 
 
The endocannabinoid (EC) system is generally viewed as a part of the 
neuroprotective endogenous mechanisms of the CNS and has been proposed 
as a target for the treatment of neuroinflammation (Mackie, 2006; Gowran et 
al, 2011; Chen et al, 2012 and 2013). Specifically, CB1 and CB2 agonists have 
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been shown to provide neuroprotection in vivo (in terms of prevention of 
behavioral impairment, microglial activation, cytokine expression, glycogen 
synthase kinase-3 activity, superoxide dismutase 1 and 2 expression and tau 
hyperphosphorilation) and in vitro (microglial mitochondrial activity, 
morphology and cytokine production) in the context of AD (Ramírez et al, 
2005; Martin-Moreno et al, 2011 and 2012; Aso et al, 2012 and 2013). Similar 
non-receptor mediated effects of cannabinoids have also been reported (see 
Iuvone et al, 2009, for a review).  
 
In addition, increased ECs levels are found after acute brain damage and 
seem to play a beneficial role against different types of insult, including 
trauma, ischemia and direct excitotoxicity, among others (Martinez-Orgado et 
al, 2007). For this reason, the increase in brain levels of ECs through the 
inhibition of the enzymes responsible for their degradation has been proposed 
as a promising therapeutic approach. For instance, recent data (Chen et al, 
2012; Piro et al, 2012) have shown that pharmacological and genetic 
inhibition of the main enzyme responsible for the degradation of 2-AG, 
monoacylglycerol lipase (MGL), decrease neuroinflammation and cytokine 
production in a mouse model of AD. Furthermore, a role for 2-AG in peri-
plaque synaptic dysfunction has been also proposed (Mulder et al, 2011). 
 
Less is known on the consequences of enhancing anandamide (AEA) levels 
by inhibiting its degradation (see Fowler et al, 2010, for review). We have 
recently reported that astrocytes lacking FAAH activity exhibited an 
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exacerbated inflammatory response that was especially evident when 
challenged with a proinflammatory stimulus, such as beta-amyloid (Benito et 
al, 2012). Furthermore, recent data have corroborated that FAAH deletion 
leads to a pro-inflammatory phenotype also in vivo, particularly involving 
microglial cells (Ativie et al, 2014; Vázquez et al, 2015). On the other hand, a 
deficit in AEA production has also been linked to the cognitive dysfunction in 
AD (Jung et al, 2011).  
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2. MATERIALS AND METHODS 
2.1. Mice 
Mice coexpressing five familial Alzheimer’s disease mutations (5xFAD) were 
purchased from Jackson Laboratories (Bar Harbor, ME, USA; Oakley et al, 
2006). Mice with deletion of the gene for FAAH (FAAH-/- mice, Cravatt et al, 
2001) in the C57BL/6J background were mated with 5xFAD mice and 
backcrossed for at least 10 generations to generate paired 5xFAD and 
5xFAD/FAAH-/- littermates. Mice used in these experiments (6 months old) 
were housed and bred in the animal facilities of Universidad Rey Juan Carlos 
(Alcorcón, Madrid, Spain). This age was chosen based in previously 
published data showing that behavioral impairment in 5xFAD mice are first 
detected around this age (Oakley et al, 2006). Pilot experiments in our 
laboratory confirmed this observation (not shown). The experimental protocol 
met the European and Spanish regulations for protection of experimental 
animals (86/609/EEC and RD 1201/2005). 
 
2.2. Pharmacological treatments 
Mice received intraperitoneal injections (i.p.) of the compounds, dissolved in a 
mixture of dimethyl sulfoxide (DMSO):Cremophor:saline (1:1:18) for 12 
consecutive days. Compounds used in this study included the FAAH inhibitor 
(3'-(aminocarbonyl)[1,1'-biphenyl]-3-yl)-cyclohexylcarbamate (URB597; 
Cayman Chemical, Ann Arbor, MI, USA; 3mg/kg) and the CB1 receptor 
antagonist N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-
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methyl-1H-pyrazole-3-carboxamide hydrochloride (SR141716, SR1, kindly 
provided by Sanofi-Aventis; 5mg/kg). 
 
2.3. Behavioral determinations 
On day 8 of treatment with the corresponding compounds or vehicle, spatial 
memory acquisition was tested with the Morris water maze test (MWM), as 
described by Vorhees and Williams (2006), for four consecutive days, four 
trials per day. Briefly, mice (N=9-17 per group) were released into opaque 
water facing the tank wall from four different positions each day and allowed 
to swim for a maximum of 60 seconds. A hidden platform (below the water 
level) was placed in the same position for the whole test and both proximal 
and distal clues were used. Mice unable to find the platform at the end of that 
period of time were placed on the platform and allowed to stay on it for 
another 60 seconds. Then mice were placed in the maze at a new start 
location and the trial repeated as described. Time spent in finding the hidden 
platform (escape latency) was recorded with the Smart 3.0 software (Panlab, 
Barcelona, Spain). 
 
In order to study a possible influence of anxiety, mice were subjected to the 
elevated plus maze (EPM) test (Trullas and Skolinick, 1993; Ramos, 2008) 
the day before the initiation of the MWM. Mice were placed at the intersection 
of the four arms of the EPM and allowed to freely explore the maze for 5 
minutes. Tests were recorded with a camera and mice were scored for time 
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spent and number of entries into the open and closed arms, center area, as 
well as for the head dipping. 70% ethanol solution was used to clean the 
maze between tests. 
 
2.4. Quantification of the expression of cytokines and enzymes by RT-PCR 
At the end of the treatment period, mice were sacrified by cervical dislocation 
and brains quickly extracted. One hemisphere was immediately frozen in 
isopentane and kept at -80C until analysis. The other hemisphere was 
immersed in 4% paraformaldehyde in PBS and subsequently embedded in 
paraffin for histological studies.  
 
Total RNA was isolated from frozen samples of hippocampus (N=9 per group) 
using Tripure Isolation Reagent (Roche Diagnostics, Manheim, Germany) 
according to manufacturer’s instructions. RNA was dissolved in RNase-free 
water and its concentration quantified by absorption at 260 nm. Aliquots were 
subjected to 1% denaturing agarose gel electrophoresis and ethidium bromide 
staining to verify the quantity and quality of RNA. Single-stranded 
complementary DNA (cDNA) was synthesized from 1 g of total RNA using 
the Transcriptor First Strand cDNA Synthesis kit (AMV) (Roche). PCR primers 
and TaqMan probes were designed by Tib Molbiol (Berlin, Germany) as 
shown in Table 1. For normalization, 18S primers and probe number 55 from 
Universal ProbeLibrary (Roche) were utilized. Gene expression was quantified 
using LightCycler FastStart DNA Master HybProbe (Roche) and Quantimix 
Easy Probes kit (Biotools, Madrid, Spain) in a LightCycler thermocycler 
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(Roche). The concentration of primers and probes were 0.5 M and 0.2 M 
respectively. PCR assays were performed using 2 l of the cDNA reaction. All 
assays were carried out twice as independent PCR runs for each cDNA 
sample. Mean values were used for further calculation. A negative (no 
template) control was measured in each of the PCR runs. Standard curves 
were calculated for quantification purposes using five-fold serial dilutions of 
cDNA from mouse brain. The transcript amounts were calculated using the 
second derivate maximum mode of the LC-software version 4.0. The specific 
transcript quantities were normalized to the transcript amounts of the 
reference gene 18S. All further calculations and statistical analyses were 
carried out with these values referred to as relative expression ratios. 
 
2.5. Quantification of cytokines by ELISA 
The measurement of interleukin-1beta (IL-1) and interleukin-6 (IL-6) protein 
levels were made using ELISA kits purchased from Raybiotech (Norcross, 
GA, USA) and manufacturer’s instructions were followed; protein 
concentration were determined in a microplate ELISA reader Multiskan EX 
(Thermo Scientific). Limits of detection of these assays are less than 2 pg/ml 
and 5 pg/ml, respectively. 
 
2.6. Immunohistochemistry 
Paraffin-embedded tissues (N=3-4 per group) were cut in 4m slices and 
transferred to slides coated with Vectabond (Vector Laboratories, Burlingame, 
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CA, USA). Once deparaffined and rehydrated, tissues were subjected to an 
antigen retrieval procedure (Benito et al, 2003) and repeatedly washed with 
PBS. Beta-amyloid aggregates were labelled with thioflavin staining. For 
immunohistochemistry, endogenous peroxidase was blocked by 50 min 
incubation at room temperature in peroxidase-blocking solution (Dako, 
Denmark). After several washes with PBS, tissues were incubated with 
primary antibody overnight at room temperature. Antibodies against markers 
of astrocytes, microglia and activated microglia (rabbit polyclonal anti-glial 
fibrillar acidic protein, GFAP; 1:1000 dilution, Dako; rabbit polyclonal anti-Iba1 
antibody; 1:2000 dilution, Wako, Osaka, Japan; rat anti-mouse monoclonal 
anti-CD68; 1:1000, BioRad, Hercules, CA, USA; respectively) were diluted in 
PBS containing 1% BSA (Sigma, St. Louis, USA) and 1% Triton x-100 
(Sigma). After the incubation, sections were washed in PBS followed by 
incubation with biotinylated goat anti-rabbit antibody (1:200) for 1 hour at 
room temperature. Avidin-biotin complex (Vector Elite; Vector) and a 
diaminobenzidine (DAB) substrate-chromogen system (Dako) were used to 
obtain a visible reaction product. Sections were dehydrated, sealed and 
coverslipped. Slides were studied and photographed with an upright 
microscope (Nikon 90i, Nikon, Tokyo, Japan) and using a DXM1200F camera. 
Quantification of the slides was performed with Metamorph (Molecular 
Devices, Sunnyvale, CA, USA) and ImageJ (NIH, MD, USA) software. 
 
Images were converted to 8-bit grayscale for analysis. Next, a threshold value 
was set (to highlight the signal corresponding to stained cells only) and the 
region of interest outlined by using the polygon selection tool (ROI tools). The 
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area occupied by thioflavin-labelled plaques, or GFAP, Iba1 or CD68 positive 
cells was quantified and divided by the total area of the selected region. 
 
2.7. Determination of brain endocannabinoid levels 
Frozen brain samples were subjected to a lipid extraction process as 
described by Patel et al, 2005. Tissue samples were weighed and placed into 
borosilicate glass culture tubes containing two ml of acetonitrile with 84pmol 
of [2H8] AEA and 186 pmol of [2H8]2-AG. Tissue was homogenized with a 
glass rod and sonicated for 30 min. Samples were incubated overnight at -20 
ºC to precipitate proteins, then centrifuged at 1500 x g to remove particulates. 
The supernatants were diluted in 300 l of methanol to recapture any lipids 
adhering to the glass tube, and dried again under N2 gas. Final lipid extracts 
were suspended in 20 l of methanol, and stored at -80 ºC until analysis. The 
contents of N-acylethanolamines (NAEs; AEA, oleoylethanolamide (OEA) and 
palmitoylethanolamide (PEA)) as well as of 2-AG were determined in the lipid 
extracts using isotope-dilution, liquid chromatography-mass spectrometry as 
described previously (Patel et al, 2005).  
 
2.8. Amyloid quantification by ELISA 
The protocol used has been previously described (Aso et al, 2012). Frozen 
mouse brain cortices were homogenized in 4 volumes (weight:volume) of TBS 
extracting buffer (140 mM NaCl, 3 mM KCl, 25 mM Tris, pH 7.4, 5 mM EDTA 
and protease inhibitor cocktail; Roche). Homogenates were centrifuged at 
100,000 g for 1 h, and the supernatants saved as the soluble fraction for A 
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quantifications. Human ELISA kits (Invitrogen, Camarillo, CA, USA) were 
used for the quantification of A1-40 and A1-42 in the brain soluble fractions, 
following the instructions provided by the manufacturer. Levels were 
normalized to the total amount of protein from each individual protein. 
 
2.9. Quantification of amyloid-related proteins by western-blot 
Protein fractions were collected from a Tri-pure extraction of hippocampal 
tissues, according to manufacturer's instructions (Roche). Lysates (30 
μg/lane) were separated by SDS-PAGE and transferred onto PVDF 
membranes (BioRad). After blocking in TTBS (10mM Tris pH 7.5, 150mM 
NaCl, 0.1% Tween 20 plus 2% bovine serum albumin) were incubated 
overnight at 4ºC, as appropriate, with: anti-APP (1:500, Merck Millipore, 
Darmstadt, Germany), anti-β-actin (1:5000, Sigma), anti-BACE1 (1:1000) and 
Presenilin 1 (1:1000, Abcam (Cambridge, UK). Membranes were incubated 
with corresponding horseradish peroxidase-conjugated secondary antibody 
(1:10,000) and were developed using a chemiluminescent reagent (ECL 
detection reagent GE Healthcare, Buckinghamshire, UK). Developed signals 
were recorded on X-ray film (Fujifilm) for densitometric analysis (ImageJ, NIH, 
MD, USA). 
 
2.10. Statistical analysis 
Results are expressed as mean ± SEM. Statistical analysis were made using 
student's t test for comparisons between two groups, analysis of variance 
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(ANOVA) with Tukey’s post-test for multiple comparisons and 2-way ANOVA 
with Bonferroni’s post-test for multiple comparisons including time course. A p 
value <0.05 was considered as statistically significant. Data were analysed 
with Graph Pad Prism software version 4.0a (San Diego, CA, USA). 
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3. RESULTS 
3.1. 5xFAD mice show memory impairment that is not modified by 
pharmacological inactivation of FAAH or by CB1 blockade. 
As has been previously reported, 5xFAD mice exhibit cognitive impairment at 
6 months of age. We confirmed this observation by using a test of memory 
acquisition. MWM data revealed that 5xFAD mice showed an impairment in 
terms of escape latency (fig 1A). Treatment with URB or SR1 did not modify 
this effect associated to the amyloid pathology (Oakley et al, 2006). 
 
3.2. The genetic inactivation of FAAH prevented the memory deficit in 5xFAD 
mice without affecting anxiety and independently of CB1 receptors. 
5xFAD/FAAH-/- mice showed a significant improvement in their ability to 
acquire spatial memory, that was more evident on the last two days of test (fig 
1 B). The treatment with the specific CB1 antagonist SR1 did not reverse this 
effect of the genetic deletion of FAAH (fig 1 C). In order to rule out a possible 
influence of anxiety levels on the MWM data, mice were subjected to the 
elevated plus maze test. Our results show an anxiolytic effect linked to the 
disease (as measured by the % of time in open arms and the index of open 
arms avoidance), but independent of the FAAH genotype (fig 1 D and E), thus 
suggesting that the improvement in memory acquisition observed in 
5xFAD/FAAH-/- mice is independent of anxiety levels. 
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3.3. Amyloid pathology leads to an increased expression of markers of 
neuroinflammation that is exacerbated by CB1 receptor blockade. 
The expression levels of several key inflammatory cytokines were significantly 
elevated as a consequence of the disease (fig 2 A to C; supplementary fig 1). 
5xFAD mice showed increased mRNA levels of IL1, IL6 and TNF in the 
hippocampus, as could be expected from the inflammatory reaction triggered 
by amyloid deposition (Oakley et al, 2006). URB treatment did not modify the 
expression of IL1 and TNF, but significantly increased the levels of IL6 (fig 
2 B). The treatment with SR1 increased the levels of the three cytokines, 
which was prevented by co-treatment with URB in the case of IL1 and IL6, 
but not TNF. The expression of COX-2 and iNOS (fig 2 D and E) was not 
affected by the disease, but was significantly increased by the treatment with 
SR1 (iNOS) or by the combination of URB and SR1 (COX-2). The SR1-
induced increase in iNOS expression was significantly reduced by co-
treatment with URB (fig 2 E). 
 
3.4. The genetic inactivation of FAAH potentiates inflammation in 5xFAD mice 
that is prevented by CB1 antagonism. 
The amyloid pathology induced an inflammatory response in the hippocampus 
that was significantly exacerbated in 5xFAD/FAAH-/- mice (fig 3; 
supplementary fig 1). This was especially evident for IL1 and IL6, but not in 
the case of the enzymes (fig 3 D and E), in which only a trend was measured. 
In addition, basal expression levels of IL6 were significantly higher in FAAH-/- 
mice as compared to WTs (fig 3 B). Finally, the treatment with SR1 
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dramatically reduced the overexpression of all inflammatory parameters (fig 
3A to E). 
 
3.5. Protein levels of cytokines are equivalent in 5xFAD and 5xFAD/FAAH-/- 
mice 
We next analysed the levels of IL1 and IL6 by ELISA. Data showed that only 
IL1 was significantly elevated in the cortex of 5xFAD mice, while those of IL6 
remained unchanged (fig 4). In both cases, no significant differences between 
5xFAD and 5xFAD/FAAH-/- mice were observed (fig 4). 
 
3.6. Amyloid levels and neuritic plaques are significantly decreased in 
5xFAD/FAAH-/- mice 
The analysis of hippocampal areas of 6 month old 5xFAD mice revealed a 
high density of amyloid plaques, as could be expected from previously 
published data (Oakley et al, 2006; fig 5 A). We found a significant decrease 
of neuritic plaques in 5xFAD/FAAH-/- mice as compared to 5xFAD mice (fig 5 
A and B). We next quantified the brain levels of the two main amyloid species 
that are responsible for plaque formation (A1-40 and A1-42) by ELISA. We 
found a dramatic decrease of both amyloid peptides in FAAH-null mice as 
compared to WT mice (fig 5 C and D), with decreases of more than 50%.   
 
3.7. APP levels are decreased in 5xFAD/FAAH-/- mice 
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We next determined whether the observed decrease in amyloid levels and 
neuritic plaques could be due to changes in several of the proteins involved in 
amyloid production. Thus, we quantified the levels of APP, BACE-1 and PSN1 
in homogenates obtained from WT, FAAH-/-, 5xFAD and 5xFAD/FAAH-/- mice 
(fig 6). Our results show that only APP levels were significantly decreased as 
a consequence of FAAH genetic inactivation (fig 6 A). 
 
3.8. Gliosis is decreased in mice lacking FAAH but microglial cells exhibit 
increased activation. 
The analysis of hippocampal tissue sections of 5xFAD and 5xFAD/FAAH-/- 
mice showed a significant reduction in plaque-associated astro- and micro-
gliosis by using GFAP and Iba1 as markers (fig 7 A and B, and C and D, 
respectively). Treatment with URB or SR1 did not modify any of these 
parameters in 5xFAD or 5xFAD/FAAH-/- mice (not shown). We also analysed 
the activational state of microglial cells by labelling with CD68, a phenotypic 
marker that is known to be up-regulated in activated microglia (Matsumura et 
al, 2015). Our results show that, contrary to the observed decrease in the total 
number of microglial cells (fig 7 C and D), levels of activated cells were similar 
in both 5xFAD and 5xFAD/FAAH-/- mice (fig 7 E and F). 
 
3.9. Endocannabinoid levels increase as a consequence of the inactivation of 
FAAH but are not affected by amyloid pathology 
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We determined the brain levels of the main N-acylethanolamines that are 
substrates for FAAH as well as those of 2-AG, an endocannabinoid that is 
metabolized by a different enzyme (MGL). We found that the pharmacological 
(i.e. URB-treated) as well as the genetic inactivation of FAAH led to significant 
increases of AEA, PEA and OEA brain levels, without affecting those of 2-AG 
(fig 8). These data are confirmative of the inactivation of FAAH in our 
experimental conditions and the subsequent increase of EC levels. It is 
important to note that no differences in the levels of ECs were observed 














We here show that i) the enhancement of the EC tone by genetically inhibiting 
the enzyme FAAH alters the production of amyloid peptides; ii) this alteration 
includes significant decreases in the amount of total APP, soluble A1-40 and 
A1-42 peptides and neuritic plaques density in the brains of 5xFAD/FAAH-/- 
mice; iii) micro- and astro-gliosis were also diminished in 5xFAD/FAAH-/- mice, 
but the amount of activated microglial cells was equivalent to that in 5xFAD 
mice; and iv) paradoxically, 5xFAD/FAAH-/- mice exhibited higher levels of 
pro-inflammatory cytokines and, specifically, of IL1.  
 
The present data confirm our previous observations of differential effect of 
pharmacological compared to genetic blockade of FAAH and subsequent 
increase in endocannabinoid levels. As previously reported for astrocytes in 
culture (Benito et al, 2012), as well as in vivo (Vázquez et al, 2015), this 
divergence is suggestive of long-term adaptations in the FAAH-/- mouse that 
are not obtained with a short-term pharmacological blockade of the enzyme. 
This may indicate that i) a maintained increase in endocannabinoids (in time 
and/or magnitude) is required for effects to be achieved; and ii) microglial cells 
seem to be particularly sensitive to these changes (Ativie et al, 2014), as 
observed after an acute insult to the brain parenchyma (Vázquez et al, 2015) 
and, as in our present report, after chronic exposure to the amyloid-induced 
inflammatory millieu.  
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The 5xFAD mouse model is a useful tool to study the effects produced by 
high levels of human amyloid in the brain and by the appearance of amyloid 
deposits in the brain parenchyma in the form of neuritic plaques (Oakley et al, 
2006). This process is an early event in the life span of 5xFAD mice, with 
plaques being evident as early as 2-3 months of life. Cognitive impairment is 
observed at 5-6 months of age and is thought to be due to the accumulation 
of these pathological structures in the hippocampus and cortex, leading to 
inflammation and loss of functional synapses. In our hands, the behavioral 
impairment in these mice was corroborated (as revealed by alterations in 
memory and anxiety) as well as the increased neuroinflammatory state 
induced by amyloid accumulation. 
 
The Morris water test relies on hippocampal-dependent spatial reference 
memory as well as on the inherent tendency of the subjects to escape from an 
aversive environment (Vorhees and Williams, 2006). We found that 
5xFAD/FAAH-/- mice had improved memory acquisition as compared to 
5xFAD mice. This is concordance with a previous report from Varvel et al 
(2007), showing that FAAH-/-  mice exhibit increased acquisition as well as 
extinction rates of spatial memory. The same group previously reported, 
however, that no differences were evident between WT and FAAH-/-  mice, 
probably due to a bias in the methodology employed (Varvel et al, 2006). This 
apparently paradoxical effect of FAAH genetic inactivation on memory has 
been previously highlighted by other authors (Panlilio et al, 2013) as CB1 
agonists are known to induce amnesic effects and increased AEA levels 
should theoretically have a similar effect. Importantly, our present data show 
 23 
that SR1 did not prevent the improvement in spatial memory observed in 
5xFAD/FAAH-/- mice, suggesting that other receptors, such as for instance 
PPAR (Mazzola et al, 2009), might be involved in this effect. Alternatively, 
experimental conditions (dose, duration) could also have an influence on this 
lack of effect of the CB1 antagonist. Finally, it is important to note that motor 
function is preserved in 5xFAD mice at 6 months of age (Jawhar et al, 2012), 
which strongly suggests that the observed effects are due to memory 
impairment, as previously observed by these authors. 
 
Also in agreement with Jawhar et al (2012), we found differences between 
WT and 5xFAD mice in anxiety as well as between FAAH-/- and 5xFAD/FAAH-
/- mice, indicating that AD pathology led to a decrease in the anxiety levels in 
both WT and FAAH-/- mice. However, we did not find significant differences 
due to the genetic inactivation of FAAH. Methodological conditions (light, 
temperature, mouse strain, etc) could account for this observation, which is 
contrast with previously published data (Moreira et al, 2008). 
 
On the other hand, amyloid pathology led to a significant increase in cytokine 
expression levels in the hippocampus of 5xFAD/FAAH-/- mice. This 
observation confirms previous in vitro (Benito et al, 2012) and in vivo 
(Mukhopadhyay et al, 2011; Ativie et al, 2014; Vázquez et al, 2015) evidence 
and underlines the profound differences that exist among ECs regarding their 
roles in pathological conditions of the CNS. Notably, URB did not modify the 
expression levels of IL1 and TNF, but significantly enhanced the levels of 
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IL6, in concordance with in vitro data by Molina-Holgado et al (1998). Kerr et 
al (2012) have recently found a similar effect of URB in the hypothalamus of 
lipopolysaccharide-treated rats. Thus, our data seem confirmative of a specific 
effect of URB on the expression of this particular cytokine, which basal levels 
were also increased in FAAH-/- mice.  
 
Currently, the most accepted opinion is that increased cytokine levels (and, 
more specifically, those of IL1) have a negative impact on cognitive function 
in AD (Mrak and Griffin, 2005; McAfoose and Baune, 2009; Rogers et al, 
2011), although controversy exists on the putative significance of mutual 
regulation between cytokines participating in long-term potentiation and 
memory (Shaftel et al, 2008; Del Rey et al, 2013). It is important to note that 
the activity of IL1 is tightly related with the endocannabinoid system, as has 
been shown by Rossi et al (2010 and 2012) and De Chiara et al (2013). 
Based on these studies and, although the significance of the increase in IL1 
expression in 5xFAD/FAAH-/- mice is still unclear, we can suggest some 
hypotheses. First, it could be a consequence of a loss of function of TRPV1 
channels, which are known to play a permissive role in the effects of IL1 both 
at the molecular and behavioral levels (Rossi et al, 2012). Furthermore, this 
TRPV1 loss of function could be exacerbated in FAAH-/- mice due to the 
proinflammatory millieu, a fact that is known to potentiate the actions of AEA 
on these channels (Singh-Tahim et al, 2005). We can thus speculate that IL1 
increased expression might be a compensatory response in order to surpass 
the loss of TRPV1 function, necessary for IL1 function, in mice lacking 
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FAAH. Alternatively, a decrease in IL1 signaling efficacy could also lead to 
the observed increase in its expression.  
 
It is important to highlight that 5xFAD/FAAH-/- mice exhibited increase mRNA 
levels of IL1, but without a significant increase in protein levels. It is 
important to highlight that we did not find any decreases in cytokine levels 
which could be expected, at least in principle, according to the significant 
decrease in neuritic plaques and accompanying gliosis observed in 
5xFAD/FAAH-/- mice; however, this was not the case and IL1 protein levels 
reached equivalent levels to those observed in 5xFAD mice. This equivalence 
was also observed for CD68-positive cells, thus suggesting an exacerbated 
inflammatory state of microglia in 5xFAD/FAAH-/- mice, that could underlay the 
sustained production of IL1 protein (Ativie et al, 2014). 
 
In addition, the increase in IL1 expression could account for the observed 
decrease in amyloid deposition which in turn would lead to a decrease in the 
gliotic response. As mentioned above, 5xFAD/FAAH-/- exhibited a signifcant 
decrease in amyloid plaques and reduced gliosis in the hippocampus. To the 
best of our knowledge, these data are the first showing a FAAH-related 
decrease in amyloid deposition in vivo and are indicative of a beneficial effect 
of FAAH inactivation and confirm previous observations by Scuderi et al 
(2011), showing that palmitoylethanolamide (one of the main substrates for 
FAAH) decreases amyloid-induced gliosis. 
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Elegant studies by Shaftel et al (2007) and Matousek et al (2012) using a 
mouse model in which IL1 expression can be spatially and temporally 
regulated, showed that an increase in IL1 production led to a decrease in 
neuritic plaque formation. This suggests that IL1 expression in AD could 
represent a beneficial response directed to counteract plaque accumulation 
within the brain parenchyma. This apparent contradiction might be also 
partially explained by previous data (Matousek et al, 2010) showing that 
increased prostaglandin levels (which are expected to occur in FAAH-/- mice, 
Kozak et al, 2002; Weber et al, 2004) prevent the cognitive impairment 
induced by IL1 overexpression. Interestingly, by using this model Matousek 
et al (2012) have recently shown that longer periods of neuroinflammation 
may result in greater plaque reduction, which could explain the discrepancy 
herein reported between FAAH-null and URB-treated mice. 
 
Our data suggest a dual role for cannabinoid CB1 receptors in the context of 
amyloid-induced neuroinflammation. The blockade of CB1 receptors 
dramatically increased the expression levels of cytokines (IL1, IL6 and 
TNF) and enzymes (iNOS) which is coincident with previous literature 
showing an antiinflammatory effect of CB1 activation (Molina-Holgado et al, 
2003; Ortega-Gutiérrez et al, 2005; Marchalant et al, 2007 and 2008). 
However, FAAH-null mice showed exacerbated inflammation that was 
reversed by SR1, which is in concordance with previous studies using 
different experimental paradigms (Mukhopadhyay et al, 2011; Rajesh et al, 
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2012). Further studies are needed to clarify the complex interactions between 
the ECS and neuroinflammation. 
 
Finally, we also found that the genetic deletion of FAAH led to significant 
changes in amyloid pathophysiology of 5xFAD mice. Thus, 5xFAD/FAAH-/- 
mice exhibited decreased production of APP, soluble A1-40 and A1-42 
peptides and neuritic plaques density. In addition, the presence of activated 
microglial cells was similar in 5xFAD and 5xFAD/FAAH-/- mice. Taken 
together with a putative anti-amyloid role of IL1 (discussed above), these 
observations suggest that the genetic inactivation of FAAH induces multiple 
effects including decreased production and formation of amyloid precipitates 
into neuritic plaques, microglial overactivation and cyotkine production. 
 
In summary, our data reveal a shift in the role of CB1 receptors in the context 
of amyloid-induced neuroinflammation that is dependent on the levels of AEA 
and, probably, other NAEs. The maintenance of increased levels of FAAH-
regulated ECs leads to a proinflammatory phenotype in vivo that may have 
paradoxically beneficial effects and that may help to explain previously 
published data regarding the effects of AEA (Clement et al, 2003).  
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LEGENDS TO FIGURES 
Figure 1: FAAH-null mice exhibit CB1-independent improved memory 
acquisition in the Morris water maze (MWM) test that is independent of 
anxiety levels. (A) 6 month-old 5xFAD mice exhibit memory impairment in the 
MWM test that reaches statistical significance in trials days 3 and 4. URB and 
SR1 did not modify the impairment in memory acquisition in 5xFAD mice. (B) 
The genetic inactivation of FAAH (5xFAD/FAAH-/-) prevented the memory 
impairment due to amyloid pathology. (C) The improvement in memory 
acquisition in FAAH-null mice is not mediated by CB1 receptors, as shown by 
the lack of effect of the treatment with SR1. (D) and (E) The effect observed in 
FAAH-null mice is not associated to a decrease in anxiety, as revealed by the 
lack of differences due to genotype in the elevated plus maze test. Note that 
both 5xFAD and 5xFAD/FAAH-/- mice show decreased anxiety levels as 
compared with their corresponding wildtypes. *p0.05 (WT vs 5xFAD mice), 
#0.05 (5xFAD vs 5xFAD/FAAH-/- mice). Two-way ANOVA followed by 
Bonferroni’s post hoc test. 
 
Figure 2: CB1 signaling is anti-inflammatory in 5xFAD mice. Changes in the 
expression levels of inflammation-related cytokines and enzymes in the 
hippocampus are exacerbated by the blockade of CB1 receptors. (A) IL1 
mRNA levels were increased as a consequence of the amyloid pathology and 
was not modified by the treatment with URB. CB1 blockade induced a 
significant increase in IL1 expression that was prevented by the co-treatment 
with URB. (B) IL6 mRNA levels were significantly elevated in 5xFAD mice and 
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were exacerbated by the treatment with URB or SR1, but not by the 
combination of both compounds. (C) TNF expression was increased in 
5xFAD mice and exacerbated by SR1 and URB+SR1 treatments. (D) COX-2 
expression was not increased by the amyloid pathology or by the treatment 
with URB or SR1, but was so by the treatment with the combination of both 
compounds. (E) iNOS mRNA levels were significantly increased by the 
treatment with SR1, an increase that was prevented by co-treatment with 
URB. *p0.05. One-way ANOVA followed by Tukey’s post hoc test. 
 
Figure 3: CB1 signaling is pro-inflammatory in 5xFAD/FAAH-/- mice. IL1 (A), 
IL6 (B) and TNF (C) expression levels were increased as a consequence the 
amyloid pathology and were exacerbated by the genetic inactivation of FAAH. 
For all three cytokines, expression was returned to basal levels by the 
treatment with SR1. Note that IL6 expression in FAAH-/- mice was also 
elevated as compared to wildtype mice. mRNA levels of COX-2 (D) and iNOS 
(E) were not significantly elevated due to amyloid pathology or by FAAH 
genetic inactivation. Treatment with SR1 significantly prevented the 
expression of both enzymes in 5xFAD/FAAH-/- mice. *p0.05. One-way 
ANOVA followed by Tukey’s post hoc test.   
 
Figure 4: IL1 and IL6 cytokine protein levels were not modified in 
5xFAD/FAAH-/- mice. (A) IL1 levels were increased as a consequence of the 
amyloid pathology, but were not changed in respect to the genotype. (B) IL6 
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was not modified either by the pathological process or the genotype. *p0.05 
(WT vs 5xFAD mice). Two-way ANOVA followed by Bonferroni’s post hoc 
test. 
 
Figure 5: 5xFAD/FAAH-/- mice exhibit decreased density of amyloid plaques 
and diminished soluble amyloid peptides (A1-40 and A1-42) in the 
hippocampus. (A) Representative photomicrographs of thioflavin stainings 
(left) of the hippocampal region (hematoxili-eosin stained, right) of a 5xFAD 
mouse (upper) and a 5xFAD/FAAH-/- mouse (lower); note the decrease in 
thioflavin signal in the sample from a 5xFAD/FAAH-/- mouse. (B) Quantification 
of hippocampal amyloid plaques (thioflavin positive) revealeda significantly 
lower presence of these pathological structures in mice lacking FAAH. A1-40 
and A1-42) (D) levels are significantly lower in 5xFAD/FAAH-/- mice. *p0.05. 
Student t test. 
 
Figure 6: Representative western blots and quantification of amyloid-related 
proteins. (A) APP levels were increased in 5xFAD mice and significantly lower 
in FAAH-deleted mice. (B) BACE-1 protein was not modified either as a 
function of the pathological process or the genotype. (C) PS-1 protein was 
significantly higher in 5xFAD mice, but was not altered by FAAH genetic 
inactivation. *p0.05 (WT vs 5xFAD mice), #0.05 (5xFAD vs 5xFAD/FAAH-/- 





Figure 7: 5xFAD/FAAH-/- mice exhibit decreased astro-and micro-gliosis in the 
hippocampus. (A) Representative photographs of GFAP immunostaining of a 
5xFAD mouse (left) and a 5xFAD/FAAH-/- mouse (right). (B) Quantification of 
hippocampal GFAP+ cells showing significant increases as a consequence of 
the amyloid pathology as well as a significant decrease in 5xFAD/FAAH-/- as 
compared to 5xFAD. (C) Representative photomicrographs of a 5xFAD mouse 
(left) and a 5xFAD/FAAH-/- mouse (right) and (D) quantification of hippocampal 
microgliosis (Iba1+); note the significant increase as a consequence of the 
pathology and the decrease due to the genotype. (E) Representative pictures 
from a 5xFAD mouse (left) and a 5xFAD/FAAH-/- mouse (right) of CD68+ cells; 
(F) densitometric quantification revealed no significant changes. Scale bar: 
100 m. *p0.05 (WT vs 5xFAD mice), #0.05 (5xFAD vs 5xFAD/FAAH-/- 
mice). Two-way ANOVA followed by Bonferroni’s post hoc test. 
 
Figure 8: Brain concentrations of FAAH-degraded NAEs are elevated in 
FAAH-/- and in URB-treated mice. Significant increases in AEA (A), PEA (B), 
and OEA (C), were found in the brains of FAAH-/- mice, as compared to WT 
mice. Importantly, concentrations of 2-AG remained unchanged (D). Note that 
no changes were observed due to the pathological process. *p0.05. One-
way ANOVA followed by Tukey’s post hoc test. 
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Supplementary figure 1: Effects of the administration of URB or SR1 to WT 
and FAAH-/- mice. IL1 (A), IL6 (B), TNF (C), and COX-2 (D) mRNA were 
not affected by the administration of any of both compounds, with the 
exception of the SR1 administration to FAAH-/- mice. iNOS mRNA levels (E) 
showed a different pattern, with a significant increase in SR1-treated WT 
mice. *p0.05. One-way ANOVA followed by Tukey’s post hoc test. 
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